Sign up for periodic reports and bulletins
FREE access; FREE of commercials; FREE to use
Posted November 28, 2012: by Bill Sardi
Heart doctors are circling the wagons in defense of digoxin which has now been found to increase the relative risk for death from any cause by 41% among patients being treated for atrial fibrillation (fluttering heart muscle in the top chambers of the heart). About one in six patients taking digoxin for an abnormal heart rhythm will die from the drug rather than their heart rhythm disorder over a 5-year period says the report published in the European Heart Journal.
Digoxin (digitalis), first approved for heart failure in 1998, was originally derived from the herb foxglove and used traditionally since the late 1700s.
Another study published in 2011 also showed that digoxin increases mortality risk among patients undergoing internal electronic conversion of their heart from implanted defibrillators. There was about a 60% increased relative risk for mortality among patients taking digoxin who had internal heart defibrillators. No mention was made of this earlier study in public comments by health authorities today who treated the problem as an isolated study. While authorities are calling for an FDA review, there was no mention of the problem posted at the FDA website today.
Digoxin use has ranged from 35% to 70% in recent atrial fibrillation studies.
Experts say: “The mechanism by which digoxin increases total mortality in patients without heart failure remains speculative.” If only modern medicine would take its blinders off in regard to nutrition. Digoxin is widely known to induce a deficiency of thiamin (vitamin B1) which can then result in heart failure. The cardiac deaths may also be secondary to a magnesium deficiency, which thiamine protects from. © 2012 Bill Sardi, Knowledge of Health, Inc.
You must be logged in to post a comment.